Sugestões
Compartilhar
Informação da revista
Vol. 89. Núm. 1.
Páginas 40-47 (Janeiro - Fevereiro 2013)
Vol. 89. Núm. 1.
Páginas 40-47 (Janeiro - Fevereiro 2013)
Original article
Open Access
The Impact of Cystic Fibrosis on the Immunologic Profile of Pediatric Patients
Visitas
5373
Daniela M. Bernardia,
Autor para correspondência
dani_miotto@yahoo.com.br

Corresponding author.
, Antonio F. Ribeirob, Tais N. Mazzolac, Maria M.S. Vilelad, Valdemiro C. Sgarbierie
a MSc in Food and Nutrition. Department of Food and Nutrition, School of Food Engineering, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil
b PhD in Child and Adolescent Health. Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, UNICAMP, Campinas, São Paulo, Brazil
c MSc in Child and Adolescent Health. Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, UNICAMP, Campinas, São Paulo, Brazil
d PhD in Biology (Immunology). Center for Investigation in Pediatrics, Department of Pediatrics, Medical School, UNICAMP, Campinas, São Paulo, Brazil
e PhD in Nutrition. Department of Food and Nutrition, School of Food Engineering, UNICAMP, Campinas, São Paulo, Brazil
Este item recebeu

Under a Creative Commons license
Informação do artigo
Abstract
Objective

To compare the immunologic state of 44 pediatric patients with cystic fibrosis (CF) with a control group consisting of 16 healthy individuals.

Methods

CF patients aged 3 to 12 years with moderate to good clinical score were selected for the study. Erythrocytic glutathione, production of reactive oxygen species, cytokines (TNF-a, IFN-g, IL-8, IL-6, IL-10) in peripheral blood mononuclear cells cultures under spontaneous and BCG- or PHA-stimulated conditions, serum concentrations of TGF-b2, IgA, IgG, IgM, IgE, and salivary IgA were evaluated.

Results

The spontaneous production of TNF-a, IL-6, and IL-10, the PHA-stimulated production of IL-6, and the serum TGF-b2, IgA, and IgG were increased in samples from CF patients. Healthy subjects had a higher production of TNF-a in response to BCG.

Conclusion

Although CF patients appeared clinically stable, the results of their peripheral blood examinations demonstrated an impact on the immune system.

Keywords:
Cystic fibrosis
Reactive oxygen species
Glutathione
Cytokines
Immunoglobulins
Resumo
Objetivo

Comparar o estado imunológico de 44 pacientes pediátricos com fibrose cística (FC) a um grupo-controle formado por 16 indivíduos saudáveis.

Métodos

Foram selecionados para o estudo pacientes com FC com idade entre 3 e 12 anos, apresentando um escore clínico moderado e bom. Foram avaliados a glutationa eritrocitária, a produção de espécies reativas de oxigênio, citocinas (TNF-a, IFN-g, IL-8, IL-6, IL-10) em culturas de células mononucleares do sangue periférico em condições espontâneas e estimuladas por BCG ou PHA, a concentração sérica de TGF-b2, IgA, IgG, IgM, IgE e IgA salivar.

Resultados

A produção espontânea de TNF-a, IL-6 e IL-10, a produção de IL-6 estimula- da por PHA e TGF-b2, IgA e IgG séricas aumentaram em amostras de pacientes com FC. Indivíduos saudáveis tiveram uma produção mais elevada de TNF-a em resposta a BCG.

Conclusão

Apesar de os pacientes com FC parecerem clinicamente estáveis, os resul- tados de seus exames de sangue periférico mostraram que houve um impacto sobre o sistema imunológico.

Palavras-chave:
Fibrose cística
Espécies reativas de oxigênio
Glutationa
Citocinas
Imunoglobulinas
O texto completo está disponível em PDF
References
[1]
B.P. O'Sullivan, S.D. Freedman.
Cystic fibrosis.
Lancet., 373 (2009), pp. 1891-1904
[2]
J.C. Cheung, P. Kim Chiaw, S. Pasyk, C.E. Bear.
Molecular basis for the ATPase activity of CFTR.
Arch Biochem Biophys., 476 (2008), pp. 95-100
[3]
M. Rottner, J.M. Freyssinet, M.C. Martínez.
Mechanisms of the noxious inflammatory cycle in cystic fibrosis.
Respir Res., 10 (2009), pp. 23
[4]
T.S. Cohen, A. Prince.
Cystic fibrosis: a mucosal immunodeficiency syndrome.
Nat Med., 18 (2012), pp. 509-519
[5]
E. Beutler.
Red Cell Metabolism.
Churchill Livingstone, (1986),
[6]
A. Emmendörffer, M. Hecht, M.L. Lohmann-Matthes, J. Roesler.
A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123.
J Immunol Methods., 131 (1990), pp. 269-275
[7]
M.P. Richardson, M.J. Ayliffe, M. Helbert, E.G. Davies.
A simple flow cytometry assay using dihydrorhodamine for the measurement of the neutrophil respiratory burst in whole blood: comparison with the quantitative nitrobluetetrazolium test.
J Immunol Methods., 219 (1998), pp. 187-193
[8]
H. Gaines, L. Andersson, G. Biberfeld.
A new method for measuring lymphoproliferation at the single-cell level in whole blood cultures by flow cytometry.
J Immunol Methods., 195 (1996), pp. 63-72
[9]
E. Boncoeur, V.S. Criq, E. Bonvin, T. Roque, A. Henrion-Caude, D.C. Gruenert, et al.
Oxidative stress induces extracellular signal- regulated kinase 1/2 mitogen-activated protein kinase in cystic fibrosis lung epithelial cells: potential mechanism for excessive IL-8 expression.
Int J Biochem Cell Biol., 40 (2008), pp. 432-446
[10]
S. Mangione, D.D. Patel, B.R. Levin, S.B. Fiel.
Erythrocytic glutathione in cystic fibrosis. A possible marker of pulmonary dysfunction.
Chest., 105 (1994), pp. 1470-1473
[11]
L.C. Lands, V. Grey, A.A. Smountas, V.G. Kramer, D. McKenna.
Lymphocyte glutathione levels in children with cystic fibrosis.
Chest., 116 (1999), pp. 201-205
[12]
L. Gao, K.J. Kim, J.R. Yankaskas, H.J. Forman.
Abnormal glutathione transport in cystic fibrosis airway epithelia.
Am J Physiol., 277 (1999), pp. L113-L118
[13]
D. Norman, J.S. Elborn, S.M. Cordon, R.J. Rayner, M.S. Wiseman, E.J. Hiller, et al.
Plasma tumour necrosis factor alpha in cystic fibrosis.
Thorax., 46 (1991), pp. 91-95
[14]
K. Balough, M. McCubbin, M. Weinberger, W. Smits, R. Ahrens, R. Fick.
The relationship between infection and inflammation in the early stages of lung disease from cystic fibrosis.
Pediatr Pulmonol., 20 (1995), pp. 63-70
[15]
T.L. Bonfield, J.R. Panuska, M.W. Konstan, K.A. Hilliard, J.B. Hilliard, H. Ghnaim, et al.
Inflammatory cytokines in cystic fibrosis lungs.
Am J Respir Crit Care Med., 152 (1995), pp. 2111-2118
[16]
E. Osika, J.M. Cavaillon, K. Chadelat, M. Boule, C. Fitting, G. Tournier, et al.
Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease.
Eur Respir J., 14 (1999), pp. 339-346
[17]
F. Karpati, F.L. Hjelte, B. Wretlind.
TNF-alpha and IL-8 in consecutive sputum samples from cystic fibrosis patients during antibiotic treatment.
Scand J Infect Dis., 32 (2000), pp. 75-79
[18]
A.L. Pukhalsky, N.I. Kapranov, E.A. Kalashnikova, G.V. Shmarina, L.A. Shabalova, S.N. Kokarovtseva, et al.
Inflammatory markers in cystic fibrosis patients with lung Pseudomonas aeruginosa infection.
Mediators Inflamm., 8 (1999), pp. 159-167
[19]
C. Moser, S. Kjaergaard, T. Pressler, A. Kharazmi, C. Koch, N. Høiby.
The immune response to chronic Pseudomonas aeruginosa lung infection in cystic fibrosis patients is predominantly of the Th2 type.
APMIS., 108 (2000), pp. 329-335
[20]
C. Wojnarowski, T. Frischer, E. Hofbauer, C. Grabner, W. Mosgoeller, I. Eichler, et al.
Cytokine expression in bronchial biopsies of cystic fibrosis patients with and without acute exacerbation.
Eur Respir J., 14 (1999), pp. 1136-1144
[21]
T.L. Noah, H.R. Black, P.W. Cheng, R.E. Wood, M.W. Leigh.
Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis.
J Infect Dis., 175 (1997), pp. 638-647
[22]
L.S. Nixon, B. Yung, S.C. Bell, J.S. Elborn, D.J. Shale.
Circulating immunoreactive interleukin-6 in cystic fibrosis.
Am J Respir Crit Care Med., 157 (1998), pp. 1764-1769
[23]
D. Nichols, J. Chmiel, M. Berger.
Chronic inflammation in the cystic fibrosis lung: alterations in inter- and intracellular signaling.
Clin Rev Allergy Immunol., 34 (2008), pp. 146-162
[24]
R.B. Moss, R.C. Bocian, Y.P. Hsu, Y.J. Dong, M. Kemna, T. Wei, et al.
Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR).
Clin Exp Immunol., 106 (1996), pp. 374-388
[25]
J.N. Rosensweig, M. Omori, K. Page, C.J. Potter, E.J. Perlman, S.S. Thorgeirsson, et al.
Transforming growth factor-beta1 in plasma and liver of children with liver disease.
Pediatr Res., 44 (1998), pp. 402-409
[26]
M.A. South, W.J. Warwick, F.A. Wolheim, R.A. Good.
The IgA system. 3. IgA levels in the serum and saliva of pediatric patients-evidence for a local immunological system.
J Pediatr., 71 (1967), pp. 645-653
[27]
E. Gugler, J.C. Pallavicini, H. Swedlow, I. Zipkin, P.A. Agnese.
Immunological studies of submaxillary saliva from patients with cystic fibrosis and from normal children.
J Pediatr., 73 (1968), pp. 548-559
[28]
M.E. Hodson, L. Morris, J.C. Batten.
Serum immunoglobulins and immunoglobulin G subclasses in cystic fibrosis related to the clinical state of the patient.
Eur Respir J., 1 (1988), pp. 701-705
[29]
W.J. Matthews Jr., M. Williams, B. Oliphint, R. Geha, H.R. Colten.
Hypogammaglobulinemia in patients with cystic fibrosis.
N Engl J Med., 302 (1980), pp. 245-249
[30]
W.B. Wheeler, M. Williams, W.J. Matthews Jr., H.R. Colten.
Progression of cystic fibrosis lung disease as a function of serum immunoglobulin G levels: a 5-year longitudinal study.
J Pediatr., 104 (1984), pp. 695-699
[31]
F. Harrison.
Microbial ecology of the cystic fibrosis lung.
Microbiology., 153 (2007), pp. 917-923
[32]
D.E. Griffith, T. Aksamit, B.A. Brown-Elliott, A. Catanzaro, C. Daley, F. Gordin, et al.
An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
Am J Respir Crit Care Med., 175 (2007), pp. 367-416
[33]
T.M. Kremer, R.G. Zwerdling, P.H. Michelson, P. O'Sullivan.
Intensive care management of the patient with cystic fibrosis.
J Intensive Care Med., 23 (2008), pp. 159-177
[34]
J.W. Costerton, P.S. Stewart, E.P. Greenberg.
Bacterial biofilms: a common cause of persistent infections.
Science., 284 (1999), pp. 1318-1322
[35]
T.H. Ottenhoff.
New pathways of protective and pathological host defense to mycobacteria.
Trends Microbiol., 20 (2012), pp. 419-428
[36]
G.B. Pier.
The challenges and promises of new therapies for cystic fibrosis.
J Exp Med., 209 (2012), pp. 1235-1239

Please, cite this article as: Bernardi DM, Ribeiro AF, Mazzola TN, Vilela MM, Sgarbieri VC. The impact of cystic fibrosis on the immunologic profile of pediatric patients. J Pediatr (Rio J). 2013;89:40-47.

Copyright © 2013. Sociedade Brasileira de Pediatria
Baixar PDF
Idiomas
Jornal de Pediatria
Opções de artigo
Ferramentas